Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Patients with untreated depression are poorly protected by shingles vaccination

Patients with untreated depression are poorly protected by shingles vaccination

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Population Health Management discusses latest information on shingles and PHN

Population Health Management discusses latest information on shingles and PHN

Shingles vaccine reduces risk of herpes zoster disease in older patients

Shingles vaccine reduces risk of herpes zoster disease in older patients

Shingles becoming more common in Australia

Shingles becoming more common in Australia

Broad spectrum sunscreens needed to block UVB and UVA

Broad spectrum sunscreens needed to block UVB and UVA

Cancer fears allayed for shingles patients

Cancer fears allayed for shingles patients

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Novartis receives EC approval for Jakavi to treat myelofibrosis

Novartis receives EC approval for Jakavi to treat myelofibrosis

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Once-daily Gralise significantly reduces pain intensity in PHN patients

Once-daily Gralise significantly reduces pain intensity in PHN patients

Herpes zoster vaccine recommendations questioned in patients on biologics

Herpes zoster vaccine recommendations questioned in patients on biologics

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Anti-TNFs increase risk for herpes zoster infections in IRD patients